By Peter A. McCullough, MD, MPH
Respiratory syncytial virus (RSV) is a common viral infection affecting infants (~3.6 million total population) mainly under age 1 year easily treated with nebulizer therapy. Urgent care, emergency room, and hospitalization can occur for serious cases and if treated early, infant mortality should not be a concern. Among the 22.4 million children under age 5 years, the annual risk of RSV hospitalization is well under 1%. The CDC estimates 100-300 RSV deaths per year under age 5 years. Likely most would be avoided with early albuterol/budesonide nebulization therapy at home.
The Bio-Pharmaceutical Complex has targeted RSV as we emerge from the pandemic as a viral threat to propagandize young parents in an all-out war against the virus. Incredibly there are prefusion antigen vaccines for pregnant mothers and adults who do not have significant risks for the disease and now Nirsevimab (Beyfortis, Sanofi, AstraZeneca) monoclonal antibodies are widely endorsed and given on the first day of life in the US since October, 2023, with no long-term safety data.
Listen to this episode with a 7-day free trial
Subscribe to Courageous Discourse™ with Dr. Peter McCullough & John Leake to listen to this post and get 7 days of free access to the full post archives.
